Recommendation 5

     

Recommendation 5Invest in research to support clinical decision-making.   

Information on congenital CMV is limited and what does exist is out of date. This is severely hampering our ability to monitor treatments and longer-term outcomes for children affected by cCMV. 

More investment is needed to gather knowledge and data on which we can make sound, evidence-based clinical decisions. Parents would welcome tests at birth that could provide guidance on the severity of symptoms their child is likely to suffer from. 

The safety and cost effectiveness of treatment during pregnancy should be evaluated. While this clearly includes research into the efficacy and cost of new drugs, attention should also be given to new diagnostic techniques such as foetal MRI or blood sampling for early identification of babies who may benefit from anti-viral treatment. 

 

     

Our Stories

It was my first pregnancy and it was all rather exciting, choosing names, all the tiny little clothes, and we’d been so looking forward to having the 20-week scan, desperate to get a... Read more
Katie, Clara's mum, says .... 30 weeks into my pregnancy with my second child I was informed in a phone call that I had contracted CMV in pregnancy. I wasn't given any more information... Read more

Latest Events

Registered charity no: 1171773